24 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2.
Bayer Pharma
Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2.
Abbvie
Selective inhibitors of protein methyltransferases.
Icahn School of Medicine At Mount Sinai
Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.
University of North Carolina at Chapel Hill
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
UNC Eshelman School of Pharmacy
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
Epizyme, Inc.
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Eli Lilly and Company
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Daiichi Sankyo Co., Ltd
Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions.
Sichuan University
Positioning of an unprecedented 1,5-oxaza spiroquinone scaffold into SMYD2 inhibitors in epigenetic space.
Gachon University
Protein Lysine Methyltransferase SMYD2: A Promising Small Molecule Target for Cancer Therapy.
Zhejiang University
HIV latency reversal agents: A potential path for functional cure?
S£O Paulo State University (Unesp)
Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.
Key Laboratory of Molecule Synthesis and Function Discovery (Fujian Province University)
Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors.
Astrazeneca
Histone methyl transferases: A class of epigenetic opportunities to counter uncontrolled cell proliferation.
Punjabi University
Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase.
Pfizer
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.
Epizyme
Discovery of Bisubstrate Inhibitors of Nicotinamide N-Methyltransferase (NNMT).
Icahn School of Medicine At Mount Sinai
